NecstGen has partnered with Paris-based biotech Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory™, a microfluidic-based platform aiming to simplify and scale CAR-T production. The collaboration will test the system’s potential to reduce cost, footprint, and manual steps in a GMP setting.
The partnership strengthens NecstGen’s role in advancing cell therapy manufacturing and highlights Astraveus’ vision for decentralized, efficient production.
Read more: https://necstgen.com/necstgen-and-astraveus-collaborate-to-evaluate-benchtop-cell-factory-technology-for-scalable-car-t-manufacturing/
December 8, 2025, The share of female professors is increasing, but the growth remains limited. With 34.2%, Leiden University ranks in the national top three, according to the...
Leiden, December 6, 2025, 12:15 PM – by Robbert Beurse - Every day, around 70,000 people in the Netherlands experience a migraine attack. The condition ranks among the five most...
The meteorological winter has begun, and with it, the flu season. Yet there is hope: the Leiden-based biotech company Leyden Labs is working on a promising innovation that could...